Evidence comparison
GnRH agonist vs. antagonist: evidence fields
Comparison of mechanism and approved uses; not a recommendation for any individual condition.
| Field | Leuprolide | Degarelix |
|---|---|---|
| Mechanism | Agonist (flare then downregulation) | Antagonist (immediate blockade) |
| Primary approved use | Endometriosis, uterine fibroids, prostate cancer, central precocious puberty, and other hormone-dependent conditions. | Advanced prostate cancer. |
| Women's health evidence | Established in selected women's health conditions. | Limited in women; primarily studied in prostate cancer. |
Sources
Primary records
- regulatory label
Gateway to current FDA-approved prescribing information. Confirm the exact product label before clinical use.
Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.